BCL2 and mantle cell lymphoma: Novel therapies, such as BTK-degraders or novel BCL2 inhibitors and novel combinations, still need to be deeper investigated but will probably have a growing role in the close future in R/R MCL patients, moreover, with progressive anticipation of other drugs in earlier therapeutic lines.